Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4870)	5/11/1998 7:45:00 PM
From: Rocketman	Respond to of 9719

Because one of the analysts said it wouldn't effect HGSI (see Boyce's post prior to this one).......ie.) a self-fulfilling prophecy. Excerpt from the Lehman analyst Matthew Murray: <<<<<<<<< Collaboration will likely have only a minimal impact on product focused genome companies like Human Genome Sciences Inc. <HGSI.O> and Millennium Pharmaceuticals Inc. <MLNM.O> because their gene discoveries have already largely been patented or companies have filed for patents. >>>>>>>>> Which is kind of contradictory since INCY has filed enormous quantities of patents on genes and ESTs. But Murray thinks that this will cause Pharmas to either forgo or hold off on subscribing to the INCY dbases. IMHO this is a really shortsighted viewpoint. After Merck did there Wash U. spoiler deal a few years back there was lots of doom and gloom about how they would put all this info into the public domain and leave INCY nothing, and of course the stock tanked........nothing could be further from the truth as time has shown. Now Merck is an elephant who really could have squashed INCY had they really seriously tried to compete back then, but they just did a peanuts spoiler effort at a University instead. Plus, INCY's dbases utilize all of this public domain info to make their data and their software all the more useful for their clients. Now INCY has Genome Systems in St. Louis who really appreciates the Merck project genomics trained labor pool of trained staff that comes out of Wash U. You can't find people trained like this just anywhere, and Merck really helped the labor pool grow. Funny how MDYN stock didn't get hit even though their capillary sequencing system has been on the market for quite some time now, and of course PKN will just squash them too......except for these funny little patent issues: <<<<<<<<<<<<<< Monday April 20, 4:02 pm Eastern Time Company Press Release Molecular Dynamics Responds to Perkin-Elmer Complaint With Denial and Countersuit SUNNYVALE, Calif.--(BW HealthWire)--April 20, 1998--Molecular Dynamics (NASDAQ: MDYN - news) today announced that it has filed its response to the complaint filed against it by the PE Applied Biosystems division of The Perkin-Elmer Corporation (''Applied Biosystems, ABI''). The Applied Biosystems complaint, filed on March 13, alleged that Molecular Dynamics' MegaBACE(TM) 1000 DNA sequencing system and FluorImager(R) 595 imaging system infringe two Applied Biosystems patents. In its response, Molecular Dynamics denies that it infringes either ABI patent, and asserts a variety of affirmative defenses against the patents, including their invalidity. In addition, Molecular Dynamics has filed a counterclaim that it owns rights under two patents which are infringed by certain Applied Biosystems sequencing systems, including the ABI PRISM 377. Jay Flatley, Molecular Dynamics' President and CEO, stated ''We would be happy to compete with ABI in the marketplace, but since they are claiming patent rights we believe are inapplicable against our products, we feel compelled to assert our patent portfolio.'' Continuing, Mr. Flatley stated, ''The company believes that our products do not in any way infringe these Applied Biosystems patents.'' Except for the historical information contained herein, the matters discussed in this news release are forward looking statements that involve risks and uncertainties, including the timely shipment of new products, the effect of competitive pressures and the other risks detailed from time to time in the Company's SEC reports, including the Annual Report on Form 10-K for the fiscal year ended December 31, 1997. Contact: Molecular Dyncamics Jay Flatley, 408/737-3000 President and Chief Executive Officer or Lynne Wagoner, 408/737-3002 Director of Finance >>>>>>>>>>>>>> Hmmmmmm, maybe MDYN will end up owning PKN????? Only time will tell...... Later, Rman